Form PTQ-1449 (REV. 8-83)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. UCAL-253/02US

SERIAL NO. 09/281,717

APPLICANT:

John D. Baxter, et al.

FILING DATE March 30, 1999 GROUP 1648 |631

PATENT D	OCUMENTS
----------	----------

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
W).	Р1	5,331,573	19 Jul 94	Balaji, et al.	364	500	14 Dec 90
₩) ,	P2	5,500,807	19 Mar 96	Lavin, et al.	364	496	21 Feb 92

FOREIGN PATENT DOCUMENTS

						TRANSLATION	
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	МО
F1							

OTHER PUBLICATIONS (including Author, Title, Date, Pertinent Pages, Etc.)

M.	D1	ADAMS et al., "Cross-validated maximum likelihood enhances crystallographic simulated annealing refinement," Proc. Natl. Acad. Sci., Vol. 94, pp. 5018-5023, 1997
mo.	D2	APRILETTI et al., "Expression of the Rat α l Thyroid Hormone Receptor Ligand Binding Domain in Escheria coli and the Use of a Ligand-induced Comformation Change as a Method for its purification to Homogeneity," Protein Expr. Purif., Vol. 6, pp.363-370, 1995
MD.	D3	BERRY et al., "Role of the two activating domains of the oestrogen receptor in the cell- type and promoter-context dependent agonistic activity of the anti-oestrogen 4- hydroyamoxifen," EMBO J., Vol. 9, No. 9, pp. 2811-2818, 1990

D4 BOURGUET et al., "Crystal Structure of the Ligand-binding domain of the Human Nuclear Receptor RXR-α," Nature, Vol. 375, pp. 377-382, 1995

D5 BRZOZOWSKI et al., "Molecular Basis of agonism and Antagonism in the oestrogen receptor," Nature, Vol. 389, pp. 753-758, 1997

CHANG et al., "A Thyroid Hormone Receptor Coactivator Negatively Regulated by the Retinoblastoma Protein," Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 9040-9045, 1997

D7 COHEN et al., "Molecular Modeling Software and Methods for Medicinal Chemistry," J. Med. Chem., Vol. 33, No. 3, pp. 883-894, 1990

D8 COLLINGWOOD et al., "A Natural Transactivation Mutation in the Thyroid Hormone β Receptor: Impaired Interaction with Putative Transcriptional Mediators," Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 248-253, 1997

D9 DESJARLAIS et al., "Using Shape Complementarily as an Initial Screen in Designing Ligands for a Receptor Binding Site of Known Three-Dimensional Structure," J. Med. Chem., Vol. 31, pp. 722-729, 1988

AMINER DATE CONSIDERED 5/8/100

EXAMINER! Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

Form PT			SERIAL NO.			
(REV. 8	-83)	. PATENT AND TRADEMARK OFFICE UCAL-253/02US	09/281,717			
	-	INFORMATION DISCLOSURE STATEMENT				
		(Use several sheets if necestary)				
		APPLICANT:	<u> </u>			
		JUL Q 1 1999 Ophn D. Baxter, et al.	Lanavin			
		March 30, 1999	1648 (63)			
		THE PROPERTY OF THE PARTY OF TH	, , , , ,			
^w.	D10	DING et al., "Nuclear Receptor-Binding Sites of Coactivators Glu Interacting Protein 1 (GRIP1) and Steroid Receptor Coactivator 1 (SRI with Different Binding Specificities," Molecular Endocrinology, Vol. 1 1998	C-1): Multiple Motif:			
MD.	D11	ENG et al., "Probing the Structure and Function of the Estrogen Red Domain by Analysis of Mutants with Altered Transactivation Characteri Cellular Biology, Vol. 17, No. 8, pp. 4644-4653, 1997				
MD.	D12	FARMER, "Drug Design," Ariens, E.J., ed., Vol. 10, pp. 119-143, Academic Press, NY, 1980				
γγΩ.	D13	FUREY et al., "'Phases' - A Program Package for the Processing and An Data From Macromolecules," Am. Crust. Assoc. Mtg. Abstr., PA 33, Vol.	9			
MD.	D14	GLASS et al., "Nuclear Receptor Coactivators," Curr. Opin. Cell Bio., Vol. 9, pp. 222-232, 1997				
MD		GREENE et al., "Monoclonal Antibodies to Human Estrogen Receptor," Proc. Natl. Acad. Sci. USA, Vol. 77, No. 9, pp. 5115-5119, 1980				
γω.	D16	GREENE et al., "Purification of T47D Human Progesterone Receptor and Immunochemical Characterization with Monoclonal Antibodies," Molecular Endocrinology, Vol. 2, No. 8, pp. 714-726, 1988				
nv. Nv. No.	D17	HEGY et al., "Carboxymethylation of the Human Estrogen Receptor Ligand-Binding Domain-Estradiol Complex: HPLC/ESMS Peptide Mapping Shows That Cysteine 447 Does Not React With Iodoacetic Acid," Stephas, W. 6:367-373 (1996)				
no.	D18	HEERY et al., "A Signature Motif in Transcriptional Co-activators Mediates Binding to Nuclear Receptors," Nature, Vol. 387, pp. 733-736, 1997				
mo.	D19 HENTTU et al., "AF-2 Activity and Recruitment of Steroid Receptor Coactivator 1 to the Estrogen Receptor Depend on a Lysine Residue Conserved in Nuclear Receptors," Molecular and Cellular Biology, Vol. 17, No. 4, pp. 1832-1839, 1997					
043	D20	HONG et al., "GRIP1, a Novel Mouse Protein That Serves as a Transcrip Yeast for the Hormone Binding Domains of Steroid Receptors," Proc. N				

No. 5, pp. 2735-2744, 1997

D22 HORWITZ et al., "Nuclear Receptor Coactivators and Corepressors," Molecular Endocrinology, Vol. 10, pp. 1167-1177, 1996

D23 JANKNETCHT et al., "Rapid and Efficient Purification of Native Histidine-tagged Protein Expressed by Recombinant Vaccinia Virus," Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 8972-

. 8976, 1991

D24 JURUTKA et al., "Mutations in the 1,25-Dihydroxyvitamin D3 Receptor Identifying C-Terminal Amino Acids Required for Transcriptional Activation That are Functionally Dissociated from Hormone Binding, Heterodimeric DNA Binding, and Interaction with Basal Transcription Factor

D21 HONG et al., "GRIP1, a Transcriptional Coactivator for the AF-2 Transactivation Domain of Steroid, Thyroid, Retinoid, and Vitamin D Receptors," Molecular and Cell Biology, Vol. 17,

IIB, in Vitro," J. Biol. Chem., Vol. 272, No.23, pp. 14592-14599, 1997

D25 KAKIZAWA et al., "Ligand-dependent Heterodimerization of Thyroid Hormone Receptor and Retinoid X Receptor," J. of Biol. Chem., Vol. 272, No. 38, pp. 23799-23804, 1997

EXAMINER* DATE CONSIDERED

Vol. 93, pp. 4948-4952, 1996

W).

MINER Thitial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

Form Pi				SERIAL NO.
(REV. 8	3-83)	PATENT AND TRADEMARK OFFICE	UCAL-253/02US	09/281,717
		INFORMATION DISCLOSURE STATEMENT		
		(Use several sheets if recessary)		
		/ %	APPLICANT:	
		JUL 0 1 1999 6	John D. Baxter, et al.	I GROUP
			FILING DATE March 30, 1999	1648 1631
				1
		RADEMARKS		
⁄wo.	D26	KAMEI et al., "A CBP Integrator Comple Inhibition by Nuclear Receptors," Cell, Vo		Activation and AP-1
7,0	D27	KUIPER et al., "Comparison of the Li	and Rinding Specificity at	nd Transcript Tissue
Λ -		Distribution of Estrogen Receptors α and		-
'WD.		1997		
	D28	KUNTZ, "Structure-Based Strategies for Dr	ug Design and Discovery " S	cience Vol 257 pp
WD.	1520	1078-1082, 1992	ug bebign und bibeever, , b	ozooc, voz. 25., pp.
W.				
Λ 5	D29	KUSSIE et al., "Structure of the MDM2		p53 · Tumor Suppressor
WD.	ŀ	Transactivation Domain," Science, Vol. 27-	1, pp. 948-953, 1996	
	D30	LANDEL et al., "Estrogen Receptor Access	ory Proteins Augment Recepto	r-DNA Interaction and
w.	1550	DNA Bending," J. Steroid Biochem. Molec. 1		
700.	_	-		
۸. ۵	D31	LANDEL et al., "The Interaction of Hum		
M.		Receptor-Associated Proteins," Molecular I	andocrinology, vol. 8, pp. 14	0/-1419, 1994
	D32	LANZENNEC et al., "Mechanistic Aspects	of Estrogen Receptor Act	ivation Probed with
Mo.		Constitutively Active Estrogen Recept		
$^{\prime}$		Interactions and Receptor Conformational	Changes," Molecular Endocri	nology, Vol. 11, pp.
		1375-1386, 1997		
_	D33	LE DOUARIN et al., "A Possible Involveme	int TIF1 α and TIF1 β in the F	Epigenetic Control of
MD.		Transcription by Nuclear Receptors," EMBO	J., Vol. 15, No. 23, pp. 670	1-6715, 1996
NO.	D34	LEE et al., "Thyroid Hormone Receptor Dir	perization Function Mans to	Concerned Subregion
NAT	1034	of the Ligand Binding Domain," Mol. Endoca	-	_
1 Mar.				
	D35	LIN et al., "A Conformation Switch in N		
m.		Hormone Binding to Corepressor Release," 1997	Mol. Cell. Biol., Vol 17, No	o. 10, pp. 6131-6138,
<u> /w·</u>		1597		
	D36	MASUYAMA et al., "Evidence for Ligand-Dep		=
m).		<pre>in Vitamin D Receptor-Activated Tran Endocrinol., Vol. 11, pp.1507-1517, 1997</pre>	scription and Coactivator	Interaction," Mol.
<u> </u>		• • • • • • • • • • • • • • • • • • • •		···
Λ. 9	D37	MENG et al., "Automated Docking with Grid	Based Energy Evaluation," J.	Computational Chem.,
'ND·	1	Vol. 13, No. 4., pp. 505-524, 1992	•	
Mo.	D38	MUELLER et al., "Complex Heterocyclic	Structures - A Challenge f	or Computer-Assisted
Ans.		Molecular Modeling," Bull. Soc. Chim. Belg	-	-
· /W).				
ΛΛς	D39	MURSHUDOV et al., "Refinement of Macro		e Maximum-Likelihood
ino.		Method," Acta Cryst., Vol. D53, pp. 240-25	5, 1997	
٨	D40	NAVIA et al., "Use of Structural Informa	tion in Drug Design," Curr.	Opin. Struct. Biol.,
/ha		Vol. 2, pp. 202-210, 1992		-
Ms. Ms. Ms.				
4.0	D41	NORMAN et al., "The Rat Growth Hormone Go		Response Elements,"
W.		J. Biol. Chem., Vol. 264, No. 20, pp. 1206	3-140/3, 1907	
	D42	NORRIS et al., "Enhancement of Estro	gen Receptor Transcriptions	al Activity by the
Mv.		Coactivator GRIP-1 Highlights the Role c	f Activation Function 2 in	Determining Estrogen
·		Receptor Pharmacology," J. Biol. Chem., Vo	1. 273, No. 12, pp. 6679-6688	3, 1998
EXAMINER		DAT	E CONSIDERED	
(h	maal	\mathcal{M}	-L1	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

Form PTO		9 U.S. DE MENT OF COMMERCE PATENT AND TRADEMAR DOE ICE	ATTY. DOCKET NO. UCAL-253/02US	SERIAL NO. 09/281,717		
	•	INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) JUL 0.1 1999	APPLICANT:			
		A THE STATE OF THE	John D. Baxter, et al. FILING DATE March 30, 1999	GROUP 1548 G		
		MADE				
402		O'DONNELL et al., "Thyroid Hormone Receptor Activation also Interfere with Receptor In Endocrinology, Vol. 5, pp. 94-99, 1991				
	D44	ONATE et al., "Sequence and Characterization of a Coactivator for the Steroid Hormon Receptor Superfamily," Science, Vol. 270, pp. 1354-1357, 1995				
MO. Mo. Mo. Mo.	D45	RADHAKRISHNAN et al., "Solution Structure of the KIX Domain of CBP Bound to th Transactivation Domain of CREB: A Model for Activator: Coactivator Interactions," Cell Vol. 91, pp. 741-752, 1997				
MD.	D46	RENAUD et al., "Crystal Structure of the RAR-γ Ligand-Binding Domain Bound to All-trans Retinoic Acid," Nature, Vol. 378, pp. 681-689, 1995				
W.	D47	SAATCIOGLU et al., "Mutations in the Conserved C-Terminal Sequence in Thyroid Hormone Receptor Dissociate Hormone-Dependent Activation from Interference with AP1-Activity," Mol Cell Biol., Vol. 17, No. 8, pp. 4687-4695, 1997				
W.	D48	SADOVSKY et al., "Transcriptional Activators Differ in Their Responses to Overexpression of TATA-Box-Binding Protein," Molecular and Cellular Biology, Vol. 15, pp. 1554-1563, 1995				
MO.	D49	SEIELSTAD et al., "Analysis of the Structur Binding Domain by Selective Proteolysis/Mas 34, pp. 12605-12615, 1995				
	1					

D50 SEIELSTAD et al., "Molecular Characterization by Mass Spectrometry of the Human Estrogen Receptor Ligand-Binding Domain Expressed in Escherichia coli," Molecular Endocrinology, Vol. 9, pp. 647-658, 1995 SHIAU et al., "Activation of the Human Estrogen Receptor by Estrogenic and Antiestrogenic Compounds in Saccharomyces cereviviae: A Positive Selection System," Gene, Vol. 179, pp. 205-210, 1996 D52 SHIBATA et al., "Role of Co-activators and Co-repressors in the Mechanism Steroid/Thyroid Receptor Action," Recent Prog. Horm. Res., Vol. 52, pp. 141-164, 1997 D53 SPENCER et al., "Steroid Receptor Coactivator-1 is a Histone Acetyltransferase," Nature, Vol. 389, pp. 194-198, 1997 D54 TAGAMI et al., "Nuclear Receptor Corepressors Activate Rather than Suppress Basai Transcription of Genes That Are Negatively Regulated by Thyroid Hormone," Molecular and "Nuclear Receptor Corepressors Activate Rather than Suppress Basal Cellular Biology, Vol. 17, No. 5, pp. 2642-2648, 1997 D55 TANENBAUM et al., "Crystallographic Comparison of the Estrogen and Progesterone Receptor's W. Ligand Binding Domains," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 5998-6003, 1998 D56 TORA et al., "The Cloned Human Oestrogen Receptor Contains a Mutation which Alters Its Hormone Binding Properties ," EMBO J., Vol. 8, No. 7, pp. 1981-1986, 1989 D57 TORCHIA et al., "The Transcriptional Co-activator p/CIP Binds CBP and Mediates Nuclear-Receptor Function," Nature, Vol. 387, pp. 677-684, 1997 D58 UESUGI et al., "Induced **()** Helix in the VP 16 Activation Domain upon Binding to a Human TAF," Science, Vol. 277, pp. 1310-1313, 1996 D59|VERLINDE et al., "Structure-Based Drug Design: Progress, Results and Challenges,"

EXAMINER*

Structure, Vol. 2, pp. 577-587, 1994

DATE CONSIDERED

MINE: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

		· · · · · · · · · · · · · · · · · · ·				
Form PTO-		U.S. DE 4ENT OF CO. PATENT AND TRADEMARK		ATTY. DOCKET NO. UCAL-253/02US		SERIAL NO. 09/281,717
-	•	INFORMATION DISCLOSURE SOTEMENTS (Use several sheets it necessary)	5	APPLICANT:		
		JUL 0. 1 1999	9	John D. Baxter, e	t al.	
			3)	FILING DATE March 30, 1999		GROUP 1648 1631
		PADEMARK				
WD2		WAGNER et al., "A Structural Role Vol. 378, pp. 690-697, 1995	for Horn	mone in the Thyro	id Hormone	e Receptor," Nature
AW2		WEBB et al., "Tamoxifen Activation of for the Cell-Specific Estrogen-Like pp. 443-456, 1995		_		
mo.		WHITE et al., "Ligand-Independent A Conserved Tyrosine," EMBO J., Vol. 1		-	-	or by Mutation of a
m. m. m.	-	WHITFIELD et al., "A Highly Conserv Vitamin D Receptor Contains Residues and for Transcriptional Activation,"	Vital	for Heterodimeriza	tion with	Retinoid X Receptor
m.		WURTZ et al., "A Canonical Structure Nat. Struct. Biol., Vol. 3, No. 1,		-	Domain of	Nuclear Receptors,"
M.		ZHU et al., "The Different Hormone-o Receptor Isoforms Is Mediated by Into 14, pp. 9048-9054, 1997				
EXAMINER*		hmft Jo22		DATE CONSIDERED	5/8/10	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

407121 v1/PA 8Q4X01!.DOC